Temodar

• Temodar is an alkylating agent used to treat specific brain tumors, including glioblastoma multiforme.
• It works by damaging the DNA of cancer cells, preventing their growth and division.
• Administration typically involves oral capsules or intravenous infusion, often in cycles.
• Common side effects include nausea, vomiting, fatigue, and myelosuppression (low blood cell counts).
• Close monitoring by a healthcare professional is essential due to potential serious side effects.

What is Temodar?

Temodar is an antineoplastic agent specifically designed to treat certain types of cancer, particularly brain tumors. It is the brand name for the generic drug temozolomide. This medication is classified as an alkylating agent, a type of chemotherapy that works by adding an alkyl group to DNA. This process damages the DNA of rapidly dividing cancer cells, preventing them from replicating and ultimately leading to their death. Its ability to cross the blood-brain barrier makes it particularly effective for treating central nervous system cancers.

Temodar Uses and Administration

Temodar is primarily used for the treatment of specific brain cancers. Its main indications include newly diagnosed glioblastoma multiforme (a highly aggressive type of brain tumor) in adults, concurrently with radiation therapy and then as maintenance treatment. It is also approved for refractory anaplastic astrocytoma, another type of malignant brain tumor, in adults who have experienced disease progression on prior therapy. The decision to use Temodar is based on a thorough medical evaluation, often including genetic testing of the tumor, such as for MGMT promoter methylation status, which can predict response to the drug.

Administration of Temodar typically involves oral capsules, which should be taken on an empty stomach, or intravenous (IV) infusion. The dosage and schedule are highly individualized, depending on the patient’s condition, body surface area, and response to treatment. It is usually given in cycles, often for 5 consecutive days every 28 days, for several cycles. Patients must adhere strictly to their prescribed regimen and report any missed doses or adverse reactions to their healthcare provider.

Temodar Side Effects and Important Safety Information

Like all chemotherapy agents, Temodar can cause a range of side effects, some of which can be serious. Common side effects often include nausea, vomiting, constipation, fatigue, headache, and loss of appetite. These are generally manageable with supportive care. More serious side effects primarily involve myelosuppression, which is a decrease in the production of blood cells by the bone marrow. This can lead to:

• Anemia: Low red blood cell count, causing fatigue and weakness.
• Leukopenia/Neutropenia: Low white blood cell count, increasing the risk of infection.
• Thrombocytopenia: Low platelet count, increasing the risk of bleeding or bruising.

Patients receiving Temodar require regular blood tests to monitor their blood cell counts. Other important safety information includes the potential for liver toxicity, opportunistic infections (due to immunosuppression), and rare but serious pulmonary events. Women of childbearing potential and men should use effective contraception during treatment and for a period after, as Temodar can cause fetal harm and affect fertility. It is crucial for patients to discuss all potential risks and benefits with their healthcare team and report any new or worsening symptoms promptly. The comprehensive Temodar drug information provided by healthcare professionals and pharmacists is vital for patient safety and effective management of treatment.